Aripiprazole efficacy in irritability and disruptive-aggressive symptoms: young mania rating scale line analysis from two, randomized, double-blind, placebo-controlled trials.
Frye
Mark A
MA
Eudicone
James
J
Pikalov
Andrei
A
McQuade
Robert D
RD
Marcus
Ronald N
RN
Carlson
Berit X
BX
D000342:Affective Symptoms / Q000188:drug therapy; D000374:Aggression / Q000187:drug effects* / Q000523:psychology; D018692:Antimanic Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D019955:Conduct Disorder / Q000188:drug therapy; D004311:Double-Blind Method; D006801:Humans; D007508:Irritable Mood / Q000187:drug effects*; D019964:Mood Disorders / Q000188:drug therapy / Q000523:psychology; D015337:Multicenter Studies as Topic; D010879:Piperazines / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales / Q000706:statistics & numerical data; D015363:Quinolones / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole